Protagenic Therapeutics Files 8-K
Ticker: PTIXW · Form: 8-K · Filed: Oct 31, 2025 · CIK: 1022899
| Field | Detail |
|---|---|
| Company | Protagenic Therapeutics, Inc.\New (PTIXW) |
| Form Type | 8-K |
| Filed Date | Oct 31, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-event, filing
Related Tickers: PTIX
TL;DR
PTIX filed an 8-K on 10/31 for an event on 10/28. Details pending.
AI Summary
Protagenic Therapeutics, Inc. filed an 8-K on October 31, 2025, reporting an event that occurred on October 28, 2025. The filing indicates a change in the company's structure or operations, as it is listed under 'Other Events' and 'Financial Statements and Exhibits'. The company, formerly known as Atrinsic, Inc., is incorporated in Delaware and headquartered in New York.
Why It Matters
This 8-K filing signals a significant event or update for Protagenic Therapeutics, Inc., which could impact investors and stakeholders by providing new information about the company's status or strategic direction.
Risk Assessment
Risk Level: medium — An 8-K filing often indicates material events, which can introduce uncertainty or opportunity, thus warranting a medium risk assessment until the specific details are analyzed.
Key Numbers
- 001-12555 — SEC File Number (Identifies the company's filing with the SEC.)
- 06-1390025 — EIN (Employer Identification Number for the company.)
Key Players & Entities
- Protagenic Therapeutics, Inc. (company) — Filer
- October 28, 2025 (date) — Earliest Event Reported
- October 31, 2025 (date) — Filing Date
- Atrinsic, Inc. (company) — Former Company Name
- Delaware (jurisdiction) — State of Incorporation
- New York (location) — Business Address City
FAQ
What specific event triggered this 8-K filing on October 28, 2025?
The filing is categorized under 'Other Events' and 'Financial Statements and Exhibits', but the specific details of the event are not provided in the header information.
What was the previous name of Protagenic Therapeutics, Inc. before Atrinsic, Inc.?
The filing lists 'NEW MOTION, INC.' and 'MPLC, Inc.' as former company names prior to 'Atrinsic, Inc.', with name change dates in 2007 and 2005 respectively.
When did Protagenic Therapeutics, Inc. change its name from Atrinsic, Inc.?
The filing indicates the date of name change from Atrinsic, Inc. was June 30, 2009.
What is Protagenic Therapeutics, Inc.'s fiscal year end?
The company's fiscal year ends on March 31.
What is the Standard Industrial Classification (SIC) code for Protagenic Therapeutics, Inc.?
The SIC code listed is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-10-31 17:08:41
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex99-1.htm (EX-99.1) — 110KB
- ex99-1_001.jpg (GRAPHIC) — 148KB
- ex99-1_002.jpg (GRAPHIC) — 130KB
- ex99-1_003.jpg (GRAPHIC) — 111KB
- ex99-1_004.jpg (GRAPHIC) — 165KB
- ex99-1_005.jpg (GRAPHIC) — 140KB
- ex99-1_006.jpg (GRAPHIC) — 105KB
- ex99-1_007.jpg (GRAPHIC) — 124KB
- ex99-1_008.jpg (GRAPHIC) — 143KB
- ex99-1_009.jpg (GRAPHIC) — 137KB
- ex99-1_010.jpg (GRAPHIC) — 115KB
- ex99-1_011.jpg (GRAPHIC) — 117KB
- ex99-1_012.jpg (GRAPHIC) — 121KB
- ex99-1_013.jpg (GRAPHIC) — 124KB
- ex99-1_014.jpg (GRAPHIC) — 114KB
- ex99-1_015.jpg (GRAPHIC) — 123KB
- ex99-1_016.jpg (GRAPHIC) — 105KB
- ex99-1_017.jpg (GRAPHIC) — 76KB
- ex99-1_018.jpg (GRAPHIC) — 131KB
- ex99-1_019.jpg (GRAPHIC) — 86KB
- ex99-1_020.jpg (GRAPHIC) — 31KB
- ex99-1_021.jpg (GRAPHIC) — 37KB
- ex99-1_022.jpg (GRAPHIC) — 84KB
- ex99-1_023.jpg (GRAPHIC) — 102KB
- ex99-1_024.jpg (GRAPHIC) — 86KB
- ex99-1_025.jpg (GRAPHIC) — 42KB
- ex99-1_026.jpg (GRAPHIC) — 149KB
- ex99-1_027.jpg (GRAPHIC) — 169KB
- ex99-1_028.jpg (GRAPHIC) — 144KB
- ex99-1_029.jpg (GRAPHIC) — 167KB
- ex99-1_030.jpg (GRAPHIC) — 127KB
- ex99-1_031.jpg (GRAPHIC) — 140KB
- ex99-1_032.jpg (GRAPHIC) — 154KB
- ex99-1_033.jpg (GRAPHIC) — 169KB
- ex99-1_034.jpg (GRAPHIC) — 164KB
- ex99-1_035.jpg (GRAPHIC) — 133KB
- ex99-1_036.jpg (GRAPHIC) — 217KB
- ex99-1_037.jpg (GRAPHIC) — 176KB
- ex99-1_038.jpg (GRAPHIC) — 153KB
- ex99-1_039.jpg (GRAPHIC) — 161KB
- ex99-1_040.jpg (GRAPHIC) — 140KB
- ex99-1_041.jpg (GRAPHIC) — 158KB
- ex99-1_042.jpg (GRAPHIC) — 141KB
- ex99-1_043.jpg (GRAPHIC) — 187KB
- ex99-1_044.jpg (GRAPHIC) — 135KB
- ex99-1_045.jpg (GRAPHIC) — 182KB
- ex99-1_046.jpg (GRAPHIC) — 187KB
- ex99-1_047.jpg (GRAPHIC) — 148KB
- ex99-1_048.jpg (GRAPHIC) — 139KB
- ex99-1_049.jpg (GRAPHIC) — 153KB
- ex99-1_050.jpg (GRAPHIC) — 150KB
- ex99-1_051.jpg (GRAPHIC) — 198KB
- ex99-1_052.jpg (GRAPHIC) — 159KB
- ex99-1_053.jpg (GRAPHIC) — 152KB
- ex99-1_054.jpg (GRAPHIC) — 191KB
- ex99-1_055.jpg (GRAPHIC) — 139KB
- ex99-1_056.jpg (GRAPHIC) — 211KB
- ex99-1_057.jpg (GRAPHIC) — 193KB
- ex99-1_058.jpg (GRAPHIC) — 135KB
- ex99-1_059.jpg (GRAPHIC) — 155KB
- ex99-1_060.jpg (GRAPHIC) — 129KB
- ex99-1_061.jpg (GRAPHIC) — 153KB
- ex99-1_062.jpg (GRAPHIC) — 165KB
- ex99-1_063.jpg (GRAPHIC) — 158KB
- ex99-1_064.jpg (GRAPHIC) — 121KB
- ex99-1_065.jpg (GRAPHIC) — 164KB
- ex99-1_066.jpg (GRAPHIC) — 175KB
- ex99-1_067.jpg (GRAPHIC) — 179KB
- ex99-1_068.jpg (GRAPHIC) — 130KB
- ex99-1_069.jpg (GRAPHIC) — 163KB
- ex99-1_070.jpg (GRAPHIC) — 158KB
- ex99-1_071.jpg (GRAPHIC) — 174KB
- ex99-1_072.jpg (GRAPHIC) — 200KB
- ex99-1_073.jpg (GRAPHIC) — 180KB
- ex99-1_074.jpg (GRAPHIC) — 125KB
- ex99-1_075.jpg (GRAPHIC) — 180KB
- ex99-1_076.jpg (GRAPHIC) — 136KB
- ex99-1_077.jpg (GRAPHIC) — 122KB
- ex99-1_078.jpg (GRAPHIC) — 176KB
- ex99-1_079.jpg (GRAPHIC) — 57KB
- ex99-1_080.jpg (GRAPHIC) — 152KB
- ex99-1_081.jpg (GRAPHIC) — 152KB
- ex99-1_082.jpg (GRAPHIC) — 193KB
- ex99-1_083.jpg (GRAPHIC) — 118KB
- ex99-1_084.jpg (GRAPHIC) — 118KB
- ex99-1_085.jpg (GRAPHIC) — 28KB
- ex99-1_086.jpg (GRAPHIC) — 39KB
- ex99-1_087.jpg (GRAPHIC) — 42KB
- ex99-1_088.jpg (GRAPHIC) — 37KB
- ex99-1_089.jpg (GRAPHIC) — 104KB
- ex99-1_090.jpg (GRAPHIC) — 135KB
- ex99-1_091.jpg (GRAPHIC) — 112KB
- ex99-1_092.jpg (GRAPHIC) — 133KB
- ex99-1_093.jpg (GRAPHIC) — 169KB
- ex99-1_094.jpg (GRAPHIC) — 146KB
- ex99-1_095.jpg (GRAPHIC) — 106KB
- ex99-1_096.jpg (GRAPHIC) — 147KB
- ex99-1_097.jpg (GRAPHIC) — 92KB
- ex99-1_098.jpg (GRAPHIC) — 163KB
- ex99-1_099.jpg (GRAPHIC) — 22KB
- ex99-1_100.jpg (GRAPHIC) — 24KB
- ex99-1_101.jpg (GRAPHIC) — 23KB
- ex99-1_102.jpg (GRAPHIC) — 23KB
- ex99-1_103.jpg (GRAPHIC) — 23KB
- ex99-1_104.jpg (GRAPHIC) — 23KB
- ex99-1_105.jpg (GRAPHIC) — 23KB
- ex99-1_106.jpg (GRAPHIC) — 22KB
- ex99-1_107.jpg (GRAPHIC) — 111KB
- ex99-1_108.jpg (GRAPHIC) — 109KB
- ex99-1_109.jpg (GRAPHIC) — 110KB
- ex99-1_110.jpg (GRAPHIC) — 115KB
- ex99-1_111.jpg (GRAPHIC) — 135KB
- ex99-1_112.jpg (GRAPHIC) — 38KB
- 0001493152-25-020444.txt ( ) — 19929KB
- ptix-20251028.xsd (EX-101.SCH) — 4KB
- ptix-20251028_def.xml (EX-101.DEF) — 26KB
- ptix-20251028_lab.xml (EX-101.LAB) — 36KB
- ptix-20251028_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROTAGENIC THERAPEUTICS, INC. Date: October 31, 2025 By: /s/ Alexander K. Arrow Name: Alexander K. Arrow Title: Chief Financial Officer